AR071419A1 - Composiciones y metodos de tratamiento del cancer de mama - Google Patents

Composiciones y metodos de tratamiento del cancer de mama

Info

Publication number
AR071419A1
AR071419A1 ARP090101509A ARP090101509A AR071419A1 AR 071419 A1 AR071419 A1 AR 071419A1 AR P090101509 A ARP090101509 A AR P090101509A AR P090101509 A ARP090101509 A AR P090101509A AR 071419 A1 AR071419 A1 AR 071419A1
Authority
AR
Argentina
Prior art keywords
breast cancer
methyl
woman
hydrogen
methods
Prior art date
Application number
ARP090101509A
Other languages
English (en)
Inventor
Joseph S Podolski
Ronald D Wiehle
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40758440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR071419(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of AR071419A1 publication Critical patent/AR071419A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para prevenir el desarrollo de cáncer de mama en pacientes bajo terapia de reemplazo hormonal o terapia con estrogenos. Reivindicacion 1: Un método para tratar el cáncer de mama, caracterizado porque comprende administrarle a una mujer que lo necesita una composicion que comprende una dosis supresora de la proliferacion del tejido de cáncer de mama de un compuesto de la formula general (1) o una sal aceptable para uso farmacéutico, hidrato o solvato del mismo, en donde: X representa un alquilo, alquenilo, alquinilo, hidrogeno, halo, monoalquilamino, dialquilamino o amino N,N-dimetilamino; R1 representa O, NOH o NO-metilo; R2 representa un hidrogeno o acetilo; y R3 representa metiloxi, formiloxi, acetoxi, acetilteonilo, glicimato, viniléter, acetiloximetilo, carbonato de metilo, halogenos, metilo, hidroxi o etiloxi. Reivindicacion 3: El método de la reivindicacion 2, caracterizado porque dicho compuesto es CDB-4124. Reivindicacion 10: El método de la reivindicacion 1, caracterizado porque dicha composicion se co-administra a dicha mujer con una cantidad eficaz de un inhibidor de aromatasa. Reivindicacion 11: El método de la reivindicacion 10, caracterizado porque el inhibidor de aromatasa se selecciona del grupo que consiste de anastrozol, letrozol, exemestano y DL-aminoglutetimida.
ARP090101509A 2008-04-28 2009-04-28 Composiciones y metodos de tratamiento del cancer de mama AR071419A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4845208P 2008-04-28 2008-04-28

Publications (1)

Publication Number Publication Date
AR071419A1 true AR071419A1 (es) 2010-06-16

Family

ID=40758440

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101509A AR071419A1 (es) 2008-04-28 2009-04-28 Composiciones y metodos de tratamiento del cancer de mama

Country Status (22)

Country Link
US (2) US20110053900A1 (es)
EP (2) EP2974772A1 (es)
JP (1) JP5576362B2 (es)
KR (1) KR101349737B1 (es)
CN (1) CN102099040B (es)
AR (1) AR071419A1 (es)
AU (1) AU2009241360B2 (es)
BR (1) BRPI0911112A2 (es)
CA (1) CA2722637C (es)
CL (1) CL2009001011A1 (es)
EA (1) EA019224B1 (es)
HK (1) HK1155084A1 (es)
IL (2) IL208845A (es)
ME (1) ME01122B (es)
MX (1) MX2010011273A (es)
MY (1) MY161549A (es)
NI (1) NI201000184A (es)
NZ (1) NZ589534A (es)
TW (1) TWI539953B (es)
UA (1) UA101192C2 (es)
WO (1) WO2009134723A1 (es)
ZA (1) ZA201007648B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011157443A1 (en) 2010-06-17 2011-12-22 N.V. Organon (11b,17a)-11-(4-(2-11c-acetyl)phenyl)-17,23-epoxy-19,24-dinorchola-4,9,20-trien-3-one
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
JP6092880B2 (ja) * 2011-10-04 2017-03-08 インヴァイヴィス ファーマスーティカルズ インコーポレーテッドＩｎｖｉｖｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 抗プロゲスチン感受性腫瘍を特定および治療する方法ならびに系
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
AU2014228990B2 (en) * 2013-03-15 2017-02-02 Aprecia Pharmaceuticals LLC Rapid disperse dosage form containing levetiracetam
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
HU230381B1 (hu) * 2014-02-17 2016-03-29 Richter Gedeon Nyrt Ipari eljárás szteroid intermedier előállítására
CA2966753A1 (en) 2014-11-17 2016-05-26 Arno Therapeutics, Inc. Onapristone extended-release compositions and methods
WO2017053793A1 (en) 2015-09-25 2017-03-30 Arno Therapeutics, Inc. Methods of making onapristone intermediates
US10548905B2 (en) 2015-12-15 2020-02-04 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
PE20190175A1 (es) 2016-03-28 2019-02-01 Incyte Corp Compuestos de pirrolotriazina como inhibidores de tam
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
US20200069702A1 (en) * 2016-12-09 2020-03-05 Repros Therapeutics Inc. Oral pharmaceutical compositions comprising an unmicronized selective progesterone receptor as active agent
AR117600A1 (es) 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
RU2679625C1 (ru) * 2018-11-08 2019-02-12 Ильясов Шамиль Сионович ПРИМЕНЕНИЕ 3-О-СУЛЬФАМОИЛОКСИ-6-ОКСА-7β-МЕТИЛ-D-ГОМО-8α-ЭСТРА-1,3,5(10)-ТРИЕН-17а-ОНА ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ВКЛЮЧАЯ ТРИЖДЫ-НЕГАТИВНУЮ ФОРМУ, И СПОСОБ ЕГО ПОЛУЧЕНИЯ

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3506785A1 (de) 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
US5446178A (en) 1987-03-18 1995-08-29 Schering Aktiengesellschaft Process for preparing 19,11β-bridged steroids
DE3866410D1 (de) 1987-04-24 1992-01-09 Akzo Nv 11-arylestranderivate und 11-arylpregnanderivate.
ES2053714T3 (es) 1987-12-12 1994-08-01 Akzo Nv Proceso para la preparacion de 11-arilesteroides.
DE3820948A1 (de) 1988-06-16 1989-12-21 Schering Ag 10ss, 11ss-ueberbrueckte steroide
DE3822770A1 (de) 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
DE3832303A1 (de) 1988-09-20 1990-04-12 Schering Ag 11ss-phenyl-14ssh-steroide
DE3917274A1 (de) 1989-05-24 1990-11-29 Schering Ag 9(alpha)-hydroxy-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
DE4042007A1 (de) 1990-12-22 1992-06-25 Schering Ag 6,7-modifizierte-11(beta)-aryl-4-estrene
US5407928A (en) 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
DE4038128A1 (de) 1990-11-27 1992-06-04 Schering Ag 8-en-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
ZA929315B (en) 1991-12-20 1993-05-24 Akzo Nv 17-spirofuran-3'-ylidene steroids.
DE4216003A1 (de) 1992-05-12 1993-11-18 Schering Ag Dissoziierte kompetitive Progesteronantagonisten
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
DE4216004B4 (de) 1992-05-12 2008-03-27 Bayer Schering Pharma Akiengesellschaft Verwendung kompetitiver Progesteronantagonisten
BR9306661A (pt) 1992-07-01 1998-12-08 Ortho Pharma Corp 1-arilsulfonil arilcarbonil E 1-arilfosfonil-3-fenil 1,4,5,6-tetra-hidropidazinas
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4434488A1 (de) 1994-09-14 1996-03-21 Schering Ag Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5576310A (en) 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
US5688810A (en) 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
JPH10512889A (ja) * 1995-02-02 1998-12-08 シェーリング アクチェンゲゼルシャフト 機能不全性子宮出血を治療する医薬を製造するためのプロゲステロンアンタゴニスト
US6861415B2 (en) * 1996-05-01 2005-03-01 The United States Of America As Represented By The Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
US5753655A (en) 1996-10-10 1998-05-19 Ortho Pharmaceutical Corporation 1-arylsulphonyl, arylcarbonyl and arylthiocarbonyl pyridazino derivatives and methods of preparation
DE19652408C2 (de) 1996-12-06 2002-04-18 Schering Ag Steroidester, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneimitteln
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
DE19809845A1 (de) 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
WO2001074840A2 (en) * 2000-03-17 2001-10-11 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregna 21-substituted 19-norpregnadienedione as antiprogestational agents
IN191020B (es) * 2000-03-28 2003-09-13 Dabur Res Foundation
SI1328276T1 (sl) * 2000-10-18 2006-04-30 Schering Ag Uporaba antiprogestinov za profilakso in zdravljenje bolezni, odvisnih od hormonov
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
US8105625B2 (en) * 2007-04-05 2012-01-31 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案

Also Published As

Publication number Publication date
EA201071250A1 (ru) 2011-04-29
IL208845A (en) 2016-08-31
JP5576362B2 (ja) 2014-08-20
US20140343022A1 (en) 2014-11-20
BRPI0911112A2 (pt) 2015-10-06
ME01122B (me) 2013-03-20
CA2722637A1 (en) 2009-11-05
IL208845A0 (en) 2011-01-31
NZ589534A (en) 2012-08-31
NI201000184A (es) 2011-08-10
CA2722637C (en) 2015-03-10
ZA201007648B (en) 2011-07-27
US20110053900A1 (en) 2011-03-03
CL2009001011A1 (es) 2009-09-25
WO2009134723A9 (en) 2010-01-21
EA019224B1 (ru) 2014-02-28
UA101192C2 (uk) 2013-03-11
JP2011518883A (ja) 2011-06-30
TW201002330A (en) 2010-01-16
IL247093A0 (en) 2016-09-29
EP2974772A1 (en) 2016-01-20
MY161549A (en) 2017-04-28
AU2009241360B2 (en) 2012-03-08
KR20110003553A (ko) 2011-01-12
KR101349737B1 (ko) 2014-02-07
HK1155084A1 (en) 2012-05-11
MX2010011273A (es) 2010-12-21
AU2009241360A1 (en) 2009-11-05
CN102099040B (zh) 2013-06-19
CN102099040A (zh) 2011-06-15
TWI539953B (zh) 2016-07-01
WO2009134723A1 (en) 2009-11-05
EP2293798A1 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
AR071419A1 (es) Composiciones y metodos de tratamiento del cancer de mama
BRPI0516243C1 (pt) uso de um precursor de esteróide sexual selecionado do grupo que consiste em dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-eno-3b,17b-diol e 4-androsten-3,17-diona, uso do referido precursor em 5 associação com um modulador de receptor de estrogênio seletivo para proteção uterina e da glândula mamária contra câncer, composição farmacêutica e kit
IL310489A (en) Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs and preparations containing them for use in cancer treatment
AR071516A1 (es) Regimenes de dosificacion con antiprogestinas que comprende la administracion de un antagonista de progesterona como el compuesto cdb-4124
AR105809A1 (es) Compuestos para el tratamiento de trastornos médicos
JP2011518883A5 (es)
AR068702A1 (es) Composiciones farmaceuticas
BR112014010223B8 (pt) uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
BRPI1006115A8 (pt) "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
RU2015107733A (ru) Терапевтические средства на основе производных диглицилиловых простых эфиров и способы их применения
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
RU2013118325A (ru) Лечение рака молочной железы
Lu et al. The effects of aromatase inhibitors and antiestrogens in the nude mouse model
JP2013542190A5 (es)
CA2571760A1 (en) New 2-substituted d-homo-estra-1,3,5(10)-trienes as inhibitors of 17.beta.-hydroxysteroid dehydrogenase type 1
JP2015522049A5 (es)
BR112014017985A8 (pt) Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
UY33740A (es) Método para tratar el cáncer de mama y cáncer de ovarios
RU2016148441A (ru) Способ лечения pr-положительного люминального а-типа рака молочной железы ингибитором pi3k пиктилисибом
Yavas et al. Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study
RU2013131241A (ru) Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
Sood et al. Relevance of aromatase inhibitors in breast cancer treatment
PE20121177A1 (es) Fulvestrant en una dosis de 500 mg para el tratamiento del cancer de mama avanzado
JP2013500324A5 (es)
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Legal Events

Date Code Title Description
FB Suspension of granting procedure